Analysis of MET kinase domain rearrangement in NSCLC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Analysis of MET kinase domain rearrangement in NSCLC

Published:2020-07 Issue: Volume:145 Page:140-143
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Zhuo Minglei,Liang Zhen,Yi Yuting,Wu Nan,Yang Xue,Zhong Jia,Chen Xiaohan,Huang Yi,Yu Zicheng,Liu Chang,Zeng Xiaoling,Gu Wenguang,Zhao Jun

Funder

National Key R&D Program of China

Science Foundation of Peking University Cancer Hospital

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference10 articles.

1. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling;Engelman;Science,2007

2. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors;Frampton;Cancer Discov.,2015

3. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas;Bao;Genome Res.,2014

4. Novel fusion transcripts in human gastric cancer revealed by transcriptome analysis;Kim;Oncogene,2014

5. The landscape of kinase fusions in cancer;Stransky;Nat. Commun.,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and genomic analysis of baseline and acquired MET fusions with an intact kinase domain in lung cancer patients;Genes & Diseases;2024-01

2. Response to Savolitinib in a Patient with Advanced Poorly Differentiated Lung Carcinoma Positive for a Novel EML4-MET Gene Fusion;OncoTargets and Therapy;2024-01

3. Molecular characterization ofMETfusions from a large real‐world Chinese population: A multicenter study;Cancer Medicine;2023-06-16

4. Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer;Lung Cancer;2023-04

5. Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin;Frontiers in Oncology;2022-08-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3